Moreover, high expression of ICAM1 and high expression of ADAM10 or ADAM17 was associated with poor clinical outcome in pancreatic adenocarcinoma patients (Figure 7E). This evidence concerns the gene ADAM17 and pancreatic adenocarcinoma.